Research highlights IBS drugs offering best risk-benefit odds - ProHealth
|
Based on analysis of more than two dozen major clinical trials, two well-studied drug therapies – rifaximin and lubiprostone – offer irritable bowel syndrome (IBS) patients the best odds of benefit without harmful side effects, according to research led by the GI Motility Lab at Cedars-Sinai Medical Center in New York. ... Besides Cedars-Sinai, other centers participating in the research included the School of Medicine at Texas Tech University’s Health Sciences Center; the UCLA Department of Medicine; Beth Israel Deaconess Medical Center; and Harvard Medical School. Funding for the study was provided by the Beatrice and Samuel A. Seaver Foundation. Read the full story >> |
Related Stories
38th Student Research Week Successful at Showcasing Secrets of Immune Defense
Student researchers at TTUHSC had the opportunity to showcase their presentation skills at the 38th Annual Student Research Week Feb. 25 – 27.
Celebrating Veterans: TTUHSC’s General Martin Clay’s Legacy of Service and Leadership
From his initial enlistment in the Army National Guard 36 years ago to his leadership in military and civilian health care management roles, Major General Martin Clay’s career has been shaped by adaptability, mission focus and service to others.
Texas Tech University Health Sciences Center School of Nursing Named Best Accelerated Bachelor of Science in Nursing Program in Texas
The TTUHSC School of Nursing Accelerated Bachelor of Science in Nursing (BSN) program has been ranked the No. 1 accelerated nursing program in Texas by RegisteredNursing.org.
Recent Stories
Texas Tech University Health Sciences Center Announces Relocation and Expansion of the TTUHSC School of Nursing Mansfield Instructional Site
TTUHSC and the City of Mansfield announced a new collaboration to relocate and expand the School of Nursing’s existing Mansfield instructional site during the Mansfield City Council meeting on Monday, Aug. 24.
TTUHSC Recognized for Commitment to Improving Experiences and Advancing Outcomes for First-Generation College Students
FirstGen Forward announced TTUHSC is a new member of the FirstGen Forward Network Class of 2026. FirstGen Forward selected TTUHSC because the university demonstrated a commitment to improving experiences and advancing success for first-generation college students.
TTUHSC Researchers Collaborate in Study of Cancer Drug’s Possible Positive Effects on Alzheimer’s Disease
A drug typically used to treat some forms of cancer may also help delay the progression of Alzheimer’s disease. Boris Decourt, Ph.D., director of the TTUHSC Laboratory on Neurodegeneration and Translational Research, is part of the Phase II trial.